OpenAlex
PricingAboutJobs
Log inGet started
Work

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

HTML

Year: 2020
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-20-3771
Authors: Han Si, Michael Kuziora, Katie J. Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn, Koustubh Ranade, Brandon W. Higgs, Kimberly C. Banks, Vikram K. Chand, Rajiv Raja
Institutions: AstraZeneca (United States), Guardant (United States), AstraZeneca (United Kingdom), Centre Hospitalier Universitaire Vaudois, Columbia University Irving Medical Center
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: tumor mutational burden, circulating tumor DNA, liquid biopsy, metastatic non-small cell lung cancer, durvalumab, tremelimumab, immune checkpoint inhibitors, predictive biomarkers
SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca
OpenAlex ID: W3114503054
FWCI: 6.694
Cites: 56
Cited by: 119
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security